Over 600,000 Californians Risk Losing Access to GLP-1 Weight-Loss Drugs

The state’s decision is part of a broader effort to address funding challenges in Medi-Cal. Governor Gavin Newsom’s administration expects the new policy to save $85 million during the 2025-2026 fiscal year and $790 million by 2028-2029.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

May 12, 2026
10 MIN READ

over 600,000 californians risk losing access to glp-1 weight-loss drugs — PlexusDx GLP-1 education

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The state’s decision is part of a broader effort to address funding challenges in Medi-Cal. Governor Gavin Newsom’s administration expects the new policy to save $85 million during the 2025-2026 fiscal year and $790 million by 2028-2029. Alongside the changes to GLP-1 coverage, other cost-saving mea

Impact on Patients

The California Department of Health Care Services has not clarified how many patients prescribed GLP-1 drugs for weight loss alone will lose access. A recent national poll found that 38% of adults who have used these medications did so exclusively for weight loss rather than to treat a chronic condition like diabetes.

The state issued guidance to providers in 2025, recommending that patients at risk of losing coverage be weaned off their medications in the fall. Providers were encouraged to explore alternative treatment options, such as dietary changes, increased exercise, and counseling. However, experts have raised concerns about the potential consequences for patients. According to interviews with the Los Angeles Times, most individuals regain weight once they stop taking GLP-1 drugs, a factor that could harm Medi-Cal participants.

A Controversial Shift

The decision to limit coverage for weight-loss prescriptions has sparked debates over the balance between cost-saving measures and patient health outcomes. As California implements this policy, the effects on affected patients, many of whom rely on Medi-Cal for access to affordable health care, remain uncertain.

With millions of dollars in savings anticipated, the state’s move is a stark example of how budget constraints are reshaping Medicaid programs nationwide. As 2026 begins, the impact of this cost-saving measure will soon be felt by hundreds of thousands of Californians.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most affordable GLP-1 option for over 600,000 californians risk losing ac?

PlexusDx offers compounded semaglutide starting at $149/mo and a Microdose GLP-1 Protocol from $129/month — both from licensed 503A compounding pharmacies, with no membership fee.

Does PlexusDx serve patients in all 50 states?

Yes. PlexusDx serves all 50 states. Five states require a scheduled live video consultation before the first prescription is issued; all others use async intake.

How does genetic testing improve GLP-1 outcomes?

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide. PlexusDx's Precision Peptide Genetic Test evaluates 150+ relevant variants to guide medication selection.

Is compounded semaglutide the same as Wegovy or Ozempic?

Compounded semaglutide uses the same active ingredient but is not FDA-approved. It is prepared under federal compounding regulations at licensed 503A compounding pharmacies, which are subject to state board of pharmacy oversight and strict quality and safety standards.

Can I use HSA or FSA funds to pay for PlexusDx?

Yes. Prescription GLP-1 medications from PlexusDx are HSA/FSA eligible with a valid prescription. PlexusDx accepts HSA and FSA cards directly at checkout.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves